Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients

Journal of Clinical Medicine

Gabriella Iannuzzo¹  Francesca Paola Iannone¹  Gianluigi Cuomo²  Giuseppe Cioffi²  Carlo Vigorito²  Giuseppe Cudemo²  Francesco Giallauria²  Anna Di Lorenzo²  Anna Maria Iannicelli²  Antonello D’Andrea³  Mario Pacileo³ 

[1] Department of Clinical Medicine and Surgery, “Federico II” University of Naples, Via S. Pansini 5, 80131 Naples, Italy;Department of Translational Medical Sciences, “Federico II” University of Naples, Via S. Pansini 5, 80131 Naples, Italy;Unit of Cardiology and Intensive Care, Umberto I Hospital, 84014 Nocera Inferiore, Italy;

关键词: dyslipidemia;    immunosuppressants;    transplant;    PCSK9;    PCSK9 inhibitors;    alirocumab;   

DOI  :  10.3390/jcm11113247

来源: DOAJ

【 摘 要 】

Dyslipidemia is a widespread risk factor in solid organ transplant patients, due to many reasons, such as the use of immunosuppressive drugs, with a consequent increase in cardiovascular diseases in this population. PCSK9 is an enzyme mainly known for its role in altering LDL levels, consequently increasing cardiovascular risk. Monoclonal antibody PCSK9 inhibitors demonstrated remarkable efficacy in the general population in reducing LDL cholesterol levels and preventing cardiovascular disease. In transplant patients, these drugs are still poorly used, despite having comparable efficacy to the general population and giving fewer drug interactions with immunosuppressants. Furthermore, there is enough evidence that PCSK9 also plays a role in other pathways, such as inflammation, which is particularly dangerous for graft survival. In this review, the current evidence on the function of PCSK9 and the use of its inhibitors will be discussed, particularly in transplant patients, in which they may provide additional benefits.

【 授权许可】

Unknown